Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease

01 Apr 20264 min read0 viewsJournal Feed

GIST

New England Journal of Medicine, Volume 394, Issue 18 , Page 1824-1835, May 7, 2026.

Clinical Editorial

Summary

New England Journal of Medicine published a clinical update in Research Highlights on 01 Apr 2026. The item focuses on Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease. Open the detail page to review the full original feed content.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

BMJ OpenRelated by Specialty

Intimate partner violence: protocol of a quasi-experimental study to increase primary care professionals ability to identify exposed individuals

Research Highlights • 25 May 2026

BMJ OpenRelated by Specialty

Efficacy and safety of clobetasol propionate ophthalmic nanoemulsion for treating intraocular inflammation and pain associated with cataract surgery: two phase 3 multicentre, randomised, placebo-controlled, double-masked clinical studies

Research Highlights • 25 May 2026

PLOS ONERelated by Specialty

Timely Integration of specialist palliative care into oncology care for patients receiving radiotherapy for bone metastases: A study procotol for the TIPZO-RT Randomized Controlled Trial

Research Highlights • 22 May 2026

PLOS ONERelated by Specialty

Cyberattacks in supply chains: A multi-case study

Research Highlights • 22 May 2026

PLOS MedRelated by Specialty

Differences in tuberculosis prevalence by sex in low- and middle-income countries over 1993–2025: A systematic review and meta-analysis

Research Highlights • 22 May 2026

CMAJRelated by Specialty

Temporal trends in risk of acute kidney injury among patients with preeclampsia in Canada: a retrospective cohort study [Research]

Research Highlights • 25 May 2026

Feed Metadata

Source

New England Journal of Medicine